| Palo Alto Networks [PANW] - Last Close: $217.24 Palo Alto Networks has officially made it to the big time. The cybersecurity firm has been selected to replace DISH Networks [DISH] in the S&P 500 starting on June 20th. PANW's admission to the index will coincide with the quarterly rebalancing of the S&P Dow Jones Indices. DISH will move down to the S&P SmallCap 600, according to a Friday statement from S&P. PANW is leading the Nasdaq 100 with a 5.1% gain on the news. My Take: PANW is already trading at a 52-week high, but admission to the S&P 500 will likely drive more demand for the stock. Now, every S&P 500 ETF and mutual fund will have to purchase shares of PANW to balance their holdings. This could give PANW significant price support in the weeks ahead. Circor [CIR] - Last Close: $31.67 Circor is breaking out on buyout news. This morning, private equity firm KKR & Co [KKR] announced it has agreed to acquire the industrial machinery maker in a $1.6 billion deal. Under the terms of the deal, CIR investors will receive $49 per common share, representing a 54% premium to the stock's Friday closing price. Circor has yet to respond to requests for public comment, but the Wall Street Journal says it's a done deal, citing sources close to the matter.
The deal is expected to close in Q4, and shares of CIR are up 49.6% on the news, making it one of the morning's top premarket stocks.
My Take: This deal just goes to show you that the Smart Money is beginning to see opportunity in high-value industrial stocks like CIR. Makes me wonder if there will be more deals like this in the future. Day One Biopharmaceuticals [DAWN] - Last Close: $13.60 Day One Bio is rallying in the wake of a recent clinical update.
On Sunday, the biopharma firm unveiled promising clinical data from a Phase 2 study of tovorafenib in pediatric brain cancer patients.
The study found tovorafenib produced "durable responses" in patients aged six months to 25 years with relapsed or progressive low-grade glioma. The drug met its primary endpoint with a 67% overall response rate and a clinical benefit rate of 93%. The median duration of responses was 12 months. Day One said it is working on a new drug application with the FDA, and it expects to complete the submission by October 2023. DAWN is up 22.7% on the upbeat clinical data. My Take: DAWN's tovorafenib could be on course for a full approval, but the final decision likely won't come until 2024. The stock has been locked in a narrow trading range, but the drug data could provide the catalyst it needs to break out. Forza X1 [FRZA] - Last Close: $1.2494 A buzz is building around Forza X1 after a recent tweet. Last Friday, the electric boat company sent out a tweet after the closing bell with the message, "Get ready for something extraordinary! Stay tuned." So far, the company hasn't delivered the big news it promised, but the market is already bubbling with anticipation. There are no additional details available on the potential announcement just yet, but share prices are rocketing higher in Monday's premarket.
FRZA is this morning's top premarket stock with a 144.9% gain, and it's also the premarket's most actively-traded stock.
My Take: FRZA could quickly reverse course if its announcement doesn't live up to expectations. Don't let FOMO cause you to get stuck holding the bag here. Be cautious here. GainersEvaxion Biotech [EVAX] >> +39.1%Adial Pharma [ADIL] >> +33.0%Dunxin Financial [DXF] >> +28.8%Biondvax Pharma [BVXV] >> +45.2%DeclinersEPAM Systems [EPAM] >> (14.5%) Aptose Biosciences [APTO] >> (93.4%)Bellerophon Therapeutics [BLPH] >> (73.8%)Mallinkrodt PLC [MNK] >> (21.6%) Science Applications International Corporation [Saic] ... AM
Sprinklr, Inc. [Cxm] ... AM
Allego N.V. [Allg] ... AM
Fusion Fuel Green Plc [Htoo] ... AM
Healthequity, Inc. [Hqy] ... PM
IDT Corporation [Idt] ... PM
Joann, Inc. [Joan] ... PM Factory orders [Apr] ... 10:00a ISM services [May] ... 10:00a | 